LOWER  ||| S:0 E:6 ||| JJR
URINARY  ||| S:6 E:14 ||| NNP
TRACT  ||| S:14 E:20 ||| NNP
SYMPTOMS  ||| S:20 E:29 ||| NNP
AND  ||| S:29 E:33 ||| CC
FUNCTIONS  ||| S:33 E:43 ||| NNP
AFTER  ||| S:43 E:49 ||| NNP
RENAL  ||| S:49 E:55 ||| NNP
TRANSPLANTATION  ||| S:55 E:71 ||| NNP
AT  ||| S:71 E:74 ||| NNP
OUR  ||| S:74 E:78 ||| NNP
HOSPITAL  ||| S:78 E:87 ||| NNP
We  ||| S:87 E:90 ||| PRP
investigated  ||| S:90 E:103 ||| VBD
lower  ||| S:103 E:109 ||| RBR
urinary  ||| S:109 E:117 ||| JJ
tract  ||| S:117 E:123 ||| NN
symptoms  ||| S:123 E:132 ||| NNS
( ||| S:132 E:133 ||| -LRB-
LUTS ||| S:133 E:137 ||| NNP
)  ||| S:137 E:139 ||| -RRB-
and  ||| S:139 E:143 ||| CC
function  ||| S:143 E:152 ||| NN
in  ||| S:152 E:155 ||| IN
patients  ||| S:155 E:164 ||| NNS
who  ||| S:164 E:168 ||| WP
had  ||| S:168 E:172 ||| VBD
undergone  ||| S:172 E:182 ||| VBN
renal  ||| S:182 E:188 ||| JJ
transplantation  ||| S:188 E:204 ||| NN
( ||| S:204 E:205 ||| -LRB-
RTx ||| S:205 E:208 ||| NNP
) ||| S:208 E:209 ||| -RRB-
.  ||| S:209 E:211 ||| .
Fifty  ||| S:211 E:217 ||| JJ
patients  ||| S:217 E:226 ||| NNS
( ||| S:226 E:227 ||| -LRB-
34  ||| S:227 E:230 ||| CD
males  ||| S:230 E:236 ||| NNS
and  ||| S:236 E:240 ||| CC
16  ||| S:240 E:243 ||| CD
females ||| S:243 E:250 ||| NNS
;  ||| S:250 E:252 ||| :
age  ||| S:252 E:256 ||| NN
16-68  ||| S:256 E:262 ||| CD
years ||| S:262 E:267 ||| NNS
)  ||| S:267 E:269 ||| -RRB-
undergoing  ||| S:269 E:280 ||| VBG
RTx  ||| S:280 E:284 ||| JJ
at  ||| S:284 E:287 ||| IN
our  ||| S:287 E:291 ||| PRP$
hospital  ||| S:291 E:300 ||| NN
were  ||| S:300 E:305 ||| VBD
included  ||| S:305 E:314 ||| VBN
in  ||| S:314 E:317 ||| IN
this  ||| S:317 E:322 ||| DT
study ||| S:322 E:327 ||| NN
.  ||| S:327 E:329 ||| .
Average  ||| S:329 E:337 ||| JJ
follow-up  ||| S:337 E:347 ||| NN
after  ||| S:347 E:353 ||| IN
RTx  ||| S:353 E:357 ||| NNP
was  ||| S:357 E:361 ||| VBD
6.1  ||| S:361 E:365 ||| CD
years  ||| S:365 E:371 ||| NNS
( ||| S:371 E:372 ||| -LRB-
range  ||| S:372 E:378 ||| NN
0.5-28 ||| S:378 E:384 ||| CD
) ||| S:384 E:385 ||| -RRB-
.  ||| S:385 E:387 ||| .
The  ||| S:387 E:391 ||| DT
pre-transplant  ||| S:391 E:406 ||| JJ
dialysis  ||| S:406 E:415 ||| NN
period  ||| S:415 E:422 ||| NN
averaged  ||| S:422 E:431 ||| VBD
2.5  ||| S:431 E:435 ||| CD
years  ||| S:435 E:441 ||| NNS
( ||| S:441 E:442 ||| -LRB-
range  ||| S:442 E:448 ||| NN
preemptive-18.6  ||| S:448 E:464 ||| CD
years ||| S:464 E:469 ||| NNS
) ||| S:469 E:470 ||| -RRB-
.  ||| S:470 E:472 ||| .
We  ||| S:472 E:475 ||| PRP
conducted  ||| S:475 E:485 ||| VBD
the  ||| S:485 E:489 ||| DT
evaluation  ||| S:489 E:500 ||| NN
of  ||| S:500 E:503 ||| IN
lower  ||| S:503 E:509 ||| JJR
urinary  ||| S:509 E:517 ||| JJ
tract  ||| S:517 E:523 ||| NN
symptoms  ||| S:523 E:532 ||| NNS
( ||| S:532 E:533 ||| -LRB-
LUTS ||| S:533 E:537 ||| NNP
)  ||| S:537 E:539 ||| -RRB-
and  ||| S:539 E:543 ||| CC
function  ||| S:543 E:552 ||| VBP
using  ||| S:552 E:558 ||| VBG
uroflowmetry  ||| S:558 E:571 ||| NNS
( ||| S:571 E:572 ||| -LRB-
UFM ||| S:572 E:575 ||| NNP
)  ||| S:575 E:577 ||| -RRB-
,  ||| S:577 E:579 ||| ,
residual  ||| S:579 E:588 ||| JJ
urine  ||| S:588 E:594 ||| JJ
measurement ||| S:594 E:605 ||| NN
,  ||| S:605 E:607 ||| ,
24h  ||| S:607 E:611 ||| FW
bladder  ||| S:611 E:619 ||| FW
diary ||| S:619 E:624 ||| FW
,  ||| S:624 E:626 ||| ,
International  ||| S:626 E:640 ||| NNP
Prostate  ||| S:640 E:649 ||| NNP
Symptom  ||| S:649 E:657 ||| NNP
Score  ||| S:657 E:663 ||| NNP
( ||| S:663 E:664 ||| -LRB-
IPSS ||| S:664 E:668 ||| NNP
) ||| S:668 E:669 ||| -RRB-
,  ||| S:669 E:671 ||| ,
QOL  ||| S:671 E:675 ||| NNP
score ||| S:675 E:680 ||| NN
,  ||| S:680 E:682 ||| ,
Overactive  ||| S:682 E:693 ||| NNP
Bladder  ||| S:693 E:701 ||| NNP
Symptom  ||| S:701 E:709 ||| NNP
Score  ||| S:709 E:715 ||| NNP
( ||| S:715 E:716 ||| -LRB-
OABSS ||| S:716 E:721 ||| NNP
)  ||| S:721 E:723 ||| -RRB-
and  ||| S:723 E:727 ||| CC
Core  ||| S:727 E:732 ||| NNP
Lower  ||| S:732 E:738 ||| NNP
Urinary  ||| S:738 E:746 ||| NNP
Tract  ||| S:746 E:752 ||| NNP
Symptom  ||| S:752 E:760 ||| NNP
Score  ||| S:760 E:766 ||| NNP
( ||| S:766 E:767 ||| -LRB-
CLSS ||| S:767 E:771 ||| NNP
) ||| S:771 E:772 ||| -RRB-
.  ||| S:772 E:774 ||| .
Average  ||| S:774 E:782 ||| JJ
first  ||| S:782 E:788 ||| JJ
desire  ||| S:788 E:795 ||| NN
to  ||| S:795 E:798 ||| TO
void  ||| S:798 E:803 ||| VB
and  ||| S:803 E:807 ||| CC
maximum  ||| S:807 E:815 ||| JJ
desire  ||| S:815 E:822 ||| NN
to  ||| S:822 E:825 ||| TO
void  ||| S:825 E:830 ||| VB
were  ||| S:830 E:835 ||| VBD
89.9  ||| S:835 E:840 ||| CD
mL  ||| S:840 E:843 ||| JJ
and  ||| S:843 E:847 ||| CC
185  ||| S:847 E:851 ||| CD
mL  ||| S:851 E:854 ||| JJ
respectively  ||| S:854 E:867 ||| NN
in  ||| S:867 E:870 ||| IN
cystometry  ||| S:870 E:881 ||| NN
before  ||| S:881 E:888 ||| IN
RTx ||| S:888 E:891 ||| JJ
.  ||| S:891 E:893 ||| .
Atrophy  ||| S:893 E:901 ||| NNP
of  ||| S:901 E:904 ||| IN
the  ||| S:904 E:908 ||| DT
bladder  ||| S:908 E:916 ||| NN
before  ||| S:916 E:923 ||| IN
RTx  ||| S:923 E:927 ||| NNP
showed  ||| S:927 E:934 ||| VBD
a  ||| S:934 E:936 ||| DT
correlation  ||| S:936 E:948 ||| NN
with  ||| S:948 E:953 ||| IN
the  ||| S:953 E:957 ||| DT
dialysis  ||| S:957 E:966 ||| NN
period ||| S:966 E:972 ||| NN
.  ||| S:972 E:974 ||| .
UFM  ||| S:974 E:978 ||| NNP
of  ||| S:978 E:981 ||| IN
post-RTx  ||| S:981 E:990 ||| NNP
was  ||| S:990 E:994 ||| VBD
maximum  ||| S:994 E:1002 ||| JJ
urinary  ||| S:1002 E:1010 ||| JJ
flow  ||| S:1010 E:1015 ||| NN
rate  ||| S:1015 E:1020 ||| NN
of  ||| S:1020 E:1023 ||| IN
21.8  ||| S:1023 E:1028 ||| CD
mL ||| S:1028 E:1030 ||| JJ
/ ||| S:1030 E:1031 ||| CD
s  ||| S:1031 E:1033 ||| NNS
and  ||| S:1033 E:1037 ||| CC
a  ||| S:1037 E:1039 ||| DT
voided  ||| S:1039 E:1046 ||| JJ
volume  ||| S:1046 E:1053 ||| NN
of  ||| S:1053 E:1056 ||| IN
287.6  ||| S:1056 E:1062 ||| NNP
mL ||| S:1062 E:1064 ||| NNP
.  ||| S:1064 E:1066 ||| .
Severe  ||| S:1066 E:1073 ||| JJ
cases  ||| S:1073 E:1079 ||| NNS
of  ||| S:1079 E:1082 ||| IN
IPSS ||| S:1082 E:1086 ||| NNP
,  ||| S:1086 E:1088 ||| ,
QOL ||| S:1088 E:1091 ||| NNP
,  ||| S:1091 E:1093 ||| ,
OABSS  ||| S:1093 E:1099 ||| NNP
and  ||| S:1099 E:1103 ||| CC
CLSS  ||| S:1103 E:1108 ||| NNP
were  ||| S:1108 E:1113 ||| VBD
not  ||| S:1113 E:1117 ||| RB
observed ||| S:1117 E:1125 ||| VBD
.  ||| S:1125 E:1127 ||| .
Average  ||| S:1127 E:1135 ||| NNP
24h  ||| S:1135 E:1139 ||| NNP
voided  ||| S:1139 E:1146 ||| JJ
volume ||| S:1146 E:1152 ||| NN
,  ||| S:1152 E:1154 ||| ,
urination  ||| S:1154 E:1164 ||| JJ
times  ||| S:1164 E:1170 ||| NNS
and  ||| S:1170 E:1174 ||| CC
nocturia  ||| S:1174 E:1183 ||| NNS
were  ||| S:1183 E:1188 ||| VBD
2,329  ||| S:1188 E:1194 ||| NNP
mL ||| S:1194 E:1196 ||| NNP
,  ||| S:1196 E:1198 ||| ,
8.2  ||| S:1198 E:1202 ||| CD
times  ||| S:1202 E:1208 ||| NNS
and  ||| S:1208 E:1212 ||| CC
0.9  ||| S:1212 E:1216 ||| CD
times  ||| S:1216 E:1222 ||| NNS
respectively ||| S:1222 E:1234 ||| RB
.  ||| S:1234 E:1236 ||| .
Polyuria  ||| S:1236 E:1245 ||| NNP
after  ||| S:1245 E:1251 ||| IN
RTx  ||| S:1251 E:1255 ||| NNP
was  ||| S:1255 E:1259 ||| VBD
observed  ||| S:1259 E:1268 ||| VBN
in  ||| S:1268 E:1271 ||| IN
21  ||| S:1271 E:1274 ||| CD
patients  ||| S:1274 E:1283 ||| NNS
( ||| S:1283 E:1284 ||| -LRB-
42 ||| S:1284 E:1286 ||| CD
% ||| S:1286 E:1287 ||| NN
) ||| S:1287 E:1288 ||| -RRB-
.  ||| S:1288 E:1290 ||| .
Aging  ||| S:1290 E:1296 ||| VBG
and  ||| S:1296 E:1300 ||| CC
vascular  ||| S:1300 E:1309 ||| JJ
lesions  ||| S:1309 E:1317 ||| JJ
such  ||| S:1317 E:1322 ||| JJ
as  ||| S:1322 E:1325 ||| IN
diabetes  ||| S:1325 E:1334 ||| NN
and  ||| S:1334 E:1338 ||| CC
cardiovascular  ||| S:1338 E:1353 ||| JJ
disease  ||| S:1353 E:1361 ||| NN
were  ||| S:1361 E:1366 ||| VBD
the  ||| S:1366 E:1370 ||| DT
most  ||| S:1370 E:1375 ||| RBS
important  ||| S:1375 E:1385 ||| JJ
factor  ||| S:1385 E:1392 ||| NN
of  ||| S:1392 E:1395 ||| IN
LUTS ||| S:1395 E:1399 ||| NNP
.  ||| S:1399 E:1401 ||| .
After  ||| S:1401 E:1407 ||| IN
RTx ||| S:1407 E:1410 ||| NNP
,  ||| S:1410 E:1412 ||| ,
LUTS  ||| S:1412 E:1417 ||| NNP
were  ||| S:1417 E:1422 ||| VBD
present  ||| S:1422 E:1430 ||| JJ
in  ||| S:1430 E:1433 ||| IN
a  ||| S:1433 E:1435 ||| DT
number  ||| S:1435 E:1442 ||| NN
of  ||| S:1442 E:1445 ||| IN
cases  ||| S:1445 E:1451 ||| NNS
after  ||| S:1451 E:1457 ||| IN
RTx ||| S:1457 E:1460 ||| JJ
.  ||| S:1460 E:1462 ||| .
Patients  ||| S:1462 E:1471 ||| NNS
undergoing  ||| S:1471 E:1482 ||| VBG
RTx  ||| S:1482 E:1486 ||| NN
has  ||| S:1486 E:1490 ||| VBZ
been  ||| S:1490 E:1495 ||| VBN
aging ||| S:1495 E:1500 ||| VBG
,  ||| S:1500 E:1502 ||| ,
it  ||| S:1502 E:1505 ||| PRP
is  ||| S:1505 E:1508 ||| VBZ
considered  ||| S:1508 E:1519 ||| VBN
necessary  ||| S:1519 E:1529 ||| JJ
to  ||| S:1529 E:1532 ||| TO
perform  ||| S:1532 E:1540 ||| VB
the  ||| S:1540 E:1544 ||| DT
evaluation  ||| S:1544 E:1555 ||| NN
of  ||| S:1555 E:1558 ||| IN
LUTS  ||| S:1558 E:1563 ||| NNP
before  ||| S:1563 E:1570 ||| IN
RTx ||| S:1570 E:1573 ||| JJ
.  ||| S:1573 E:1575 ||| .
